Evidence map›Paper›PMID 29666669›Full record

ArticleWorld journal of gastrointestinal oncology2018

Corentin Richard, Julie Niogret, Romain Boidot, Francois Ghiringhelli

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Metastatic pancreatic acinar cell carcinoma withJournal of gastrointestinal oncology · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Corentin RichardPlatform of Transfer in Oncology, Center GF Leclerc, Dijon 21000, France.
Julie NiogretDepartment of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon 21000, France.
Romain BoidotPlatform of Transfer in Oncology, Center GF Leclerc, Dijon 21000, France.
Francois GhiringhelliPlatform of Transfer in Oncology, Center GF Leclerc, Dijon 21000, France.
Centre Georges François Leclerc · FRCentre de recherche Translationnelle en Médecine moléculaire · FRUniversité Bourgogne Franche-Comté · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic acinar cell carcinoma (PACC) is a rare cancer. When the tumor is metastatic, few therapeutic options are available. Precision medicine using next-generation sequencing is defined by the administration of drugs based on the tumor genetic mutations. The usage of precision medicine for finding new therapeutic options for rare cancers is an emerging field. We have reported here the case of a patient bearing a multitreated metastatic PACC. This patient underwent somatic and constitutional exome analyses. The analyses revealed in the liver metastasis an amplification of the

Indexed as

Acinar cell carcinomaExomeGenetic mutationsPancreatic cancerPrecision medicine

Identifiers

PMID29666669
PMCPMC5900454
OpenAlexW2802408502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.